$TLSA

Tiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August

BTIG initiated coverage of Tiziana Life Sciences (TLSA) with a Buy rating and $7 price target, citing its Treg-based approach to treating neurodegenerative diseases. The company's foralumab nasal spray aims to reduce CNS inflammation, with promising imaging data in SPMS, MSA, and Alzheimer's. BTIG highlighted the INFORM-MS trial as a key near-term catalyst.

Tiziana Life Sciences (TLSA) will present Phase 2a BANYAN trial data on intranasal foralumab for ALS at ALS Nexus 2026. The trial, conducted via the Healey ALS MyMatch program, aims to assess safety, biomarkers, and clinical effects. TLSA's stock closed at $1.14, up 1.79%, and is up 1.15% in pre-market trading.

Jefferies says Parkinson’s drug development is shifting toward neuroinflammation, while still pursuing alpha-synuclein. It estimates the addressable early US and EU population could exceed 2 million by 2035, implying a ~$8 billion disease-modifying therapy market. It cites Roche’s prasinezumab missed endpoints twice but moved to Phase III, and Denali’s BIIB122 failed broadly. Companies mentioned include Ventyx (VTYX), BioVie (BIVI), and Tiziana (TLSA).

Elrifi Ivor (Chief Executive Officer) purchased 321,423 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at an average of $0.99 ($0.97–$1.00, $0.32M total) across 2 trades over 2026-08-04 to 2026-08-05.

Elrifi Ivor (Chief Executive Officer) purchased 667,000 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at $1.00 ($0.67M total) on 2026-08-03.

Friday’s US market ended higher, with the Nasdaq up about 1% to 25,373, the S&P 500 up 0.7% to 7,489, and the Dow up 0.5% to 52,485, led by a tech rebound. The article cites company updates including Roblox, Strategy (MSTR), Rivian, Reddit, and Coinbase after their Q2 results, plus clinical and rare-earth project news for several smaller firms.

Tiziana Life Sciences (NASDAQ: TLSA) reported quantitative PET imaging results from the third patient in its Phase 2 trial of intranasal foralumab for Multiple System Atrophy. The company said post-dosing scans showed reduced neuroinflammatory activity, including up to a 34% drop in SUV and 26% in SUVR. TLSA shares were up 6.19% to $1.04.

BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.

Tiziana Life Sciences (NASDAQ:TLSA) said the last patient has received a first intranasal dose of foralumab in its Phase 2a trial for non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind study targets up to 48 patients and compares two doses vs placebo. Topline data are expected late Q3/early Q4 2026, with results planned for October 2026.